96 well plate for chemosensitivity testing

Pharmaceutical Drug Development

The Critical Path from Bench to Bedside

A recent analysis in Forbes magazine stated that the cost to bring a new drug to market has reached $5 billion. While the cost of each individual compound comes closer to $350 million, the fact that 95 percent of new agents fail to achieve FDA approval burdens the industry with enormous un-recouped R&D expenses. 

As the costs of drug development continue to climb, the early identification of disease specific, combinatorial and synergy analyses could streamline clinical development and curtail unnecessary expenditure of resources in getting your new compounds to market. 

For over 20 years, Rational Therapeutics has been cost-effectively assisting pharmaceutical and biotechnology firms streamline the research process and more rapidly provide information not available within the current drug development process. Our low-cost EVA-PCD functional platform allows us to analyze the activity of your new compounds in multiple disease types at a fraction of the cost of other research avenues, identifying the most responsive diseases and eliminating tumor types with little activity. Additionally, we can explore combinatorial potential, as well as synergy and sequence dependence. 

Having proven the capacity of this platform to predict the activity of drugs like 2-CDA,[1] the Gemcitabine plus CDDP combination[2] and the EGFr antagonists,[3] Rational Therapeutics is actively engaged in the study of the newest classes of compounds which target a wide variety of cellular signaling pathways. The EVA-PCD platform has recently been successful in the identification of a novel small molecule WNT inhibitor as reported in the lead article in PNAS April 2011.[4] 

The EVA-PCD platform has been shown to correlate with clinical response, time to progression and survival in hematologic and solid tumors[5]. It recently provided a two-fold improvement in response (p = 0.0015) and near two-fold improvement in median overall survival (21.3 vs. 12.5 month) in previously untreated metastatic NSCLC3. A meta-analysis of 2,581 patients revealed a 2.04 fold improvement in response and 1.44 fold improvement in 1 year survival.[6] 

Call us today at 1-800-542-4357 or Contact Us to inquire about partnering with Rational Therapeutics to streamline your clinical development, curtail costs and get your novel agents to market sooner.

[1] Nagourney RA, Evans SS, Messenger JC, Dill PA, et al: 2-Chlorodeoxyadenosine activity and cross-resistance patterns in primary cultures of human hematologic neoplasms.  Br J Cancer 67:10-14, 1993.

[2] Nagourney RA, Deoxynucleoside Analogs in Cancer Therapy, (ed) G Peters, Humana Press 2006.

[3] Nagourney RA, et al. Functional Profiling of Human Tumors in Primary Culture: A Platform for Drug Discovery and Therapy Selection: Proc AACR, 2008.

[4] Gonsalvez FC, et al. RNAi-Based Screen Identifies Three New Classes of Small Molecule Inhibitors of The Wnt/Wingless Signaling Pathway. PNAS Vol 108, No 15:5954-5963, April 2011.

[5] Nagourney RA. Ex Vivo Programmed Cell Death and the Prediction of Response to Chemotherapy. Curr Treat Options in Oncol. 7:103-110, 2006.

[6] Apfel, C.et al Accuracy and Clinical Utility Of In Vitro Cytometric Profiling To Personalize Chemotherapy: Preliminary Findings Of A Systematic Review And Meta-Analysis. Amer Soc of Clin Oncol 2013 (Abst #e22188.